Is Recursion Pharmaceuticals (RXRX) The Best Penny Stocks According to Billioanires?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Best Penny Stocks to Invest In According to Billionaires. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a biotechnology company that is building an AI-native discovery platform to industrialize drug discovery. Although still in the clinical stage, the company generates much of its revenue from key partnerships and collaborations with companies such as Takeda Pharmaceutical Co, Roche, Genentech, and more.

​The stock gained roughly 19% over the past month. The gains were driven by Cathie Wood’s ARK Investment buying 260,000 shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) on June 24.

​In addition, the company also highlighted clinical progress in its fiscal Q1 2026 earnings, released on May 6. The company noted that REC-1245, which is an RBM39-targeting cancer drug, showed good early safety and predictable dosing in its first 16 patients. Moreover, the REC-4881, which is aimed at the genetic disease FAP, also posted strong Phase 2 results and prompted FDA talks towards approval; updates for this candidate are expected in late 2026.

​Financially, the company reported $6.5 million in revenue for the quarter, which was down from $14.7 million a year ago, due to a phase of the Roche partnership that was completed last year, so there’s less revenue to recognize now. Notably, Recursion was able to reduce its net loss to $117.5 million. This is roughly half of last year’s $202.5 million.

​The Street remains bullish on the stock, with analysts expecting more than 76% upside from the current level.

​Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a biotechnology company focused on using AI, automation, and data science to industrialize drug discovery.

READ NEXT:  10 Good Stocks to Invest in Now and 10 Most Undervalued US Stocks According to Hedge Funds. 

Disclosure: None. Follow Insider Monkey on Google News.